Uncategorized Archives - Page 28 of 145

MondayDec 11, 2023 11:15 am

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development…

MondayDec 11, 2023 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023 Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24% In December 2022, the company effected a 1-for-30…

FridayDec 08, 2023 9:00 am

The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles

The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications The applications of nanotechnology are wide-ranging, from industrial-scale catalysis and modern electronics to precision medicine and quantum technology Clene Inc., a late clinical-stage biopharmaceutical company, has applied nanotechnology alongside other science concepts in the development of catalytically active nanocrystals The catalytic activities…

WednesdayDec 06, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study

During the live type-B meeting, PaxMedica discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One HAT, also called African Sleeping Sickness The FDA is allowing PaxMedica to use previous data from early tests of suramin to begin developing the drug for use in current cases of HAT PaxMedica received constructive feedback, which will aid in completing the remaining work necessary to file a New Drug Application (“NDA”), expected in the second half of 2024 The global ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42…

TuesdayDec 05, 2023 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline

PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second…

MondayNov 27, 2023 10:30 am

SOHM Inc. (SHMN) Is ‘One to Watch’

In August 2023, SOHM signed an LOI with CGA Intellectual Holdings Inc. to acquire disruptive stem cell technology and patents The company announced in July 2023 it had closed on the needed financing for its various ongoing projects SOHM announced in April 2023 it had signed an exclusive distribution agreement for its latest product, the anticonvulsant Levetiracetam The company in March 2023 introduced its new topical skincare line of products SOHM (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills,…

WednesdayNov 22, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was…

WednesdayNov 22, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs

Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated Clene is focusing on central nervous system (“CNS”) disorders like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”) Its lead investigational product, CNM-Au8(R), has so far demonstrated a good safety and tolerability profile, with Phase 2 trials suggesting efficacy in ALS patients Nanotechnology has attracted a great deal of the scientific community’s attention thanks to…

TuesdayNov 21, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)

Longeveron recently released topline results from its Phase 2a trial evaluating Lomecel-B(TM) as a potential treatment for mild AD The study met its primary safety endpoint across all four study groups and showed positive and statistically significant results in secondary endpoint involving the Composite Alzheimer’s Disease Score (“CADS”) for Lomecel-B(TM) and components of the CADS The positive results are expected to form the basis for further development of Lomecel-B(TM) as a potential treatment for mild AD Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions for which there is an unmet medical need, announced…

ThursdayNov 16, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company’s lead investigational product CNM-Au8(R) The 24-month long-term data cut from the open-label extension of the RESCUE-ALS study showed a significant median survival benefit of 19.3 months, a significant 52% decreased risk of ALS clinical worsening events, and a 75% decreased risk of long-term all-cause mortality Clene also summarized long-term follow-up data from the HEALEY ALS platform trial, which demonstrated significantly…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles

PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study

PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline

SOHM Inc. (SHMN) Is ‘One to Watch’

Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer

Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs

Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)

Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search